DeepMed Research

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: chemoradiotherapy （CRT）+sintilimab 1
Drug: CRT+sintilimab 2

First Posted Date: 2024-06-21

Last Posted Date: 2024-06-21

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT06468644

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06463834

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: Nituzumab
Drug: Serplulimab

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-12

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 37

Registration Number: NCT06455072

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer Recurrent

Interventions: Drug: AK104
Drug: Recombinant Human Adenovirus 5 Injection

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-12

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 37

Registration Number: NCT06455046

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Phase 2

Not yet recruiting

Conditions: Leptomeningeal Metastasis

Interventions: Drug: Double Dose of Third-generation EGFR-TKI
Drug: Intrathecal Pemetrexed

First Posted Date: 2024-06-04

Last Posted Date: 2024-06-04

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 112

Registration Number: NCT06441045

Locations: 🇨🇳
Gen Lin, Fuzhou, Fujian, China

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Phase 2

Not yet recruiting

Conditions: Immunotherapy Gastroesophageal Junction

Interventions: Drug: Tislelizumab
Drug: Anlotinib
Drug: Oxaliplatin
Drug: Tegafur

First Posted Date: 2024-05-02

Last Posted Date: 2024-05-07

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 28

Registration Number: NCT06396585

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Phase 2

Recruiting

Conditions: Mid-low Rectal Cancer

Interventions: Radiation: Short-course Radiotherapy
Drug: Tislelizumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2024-03-27

Last Posted Date: 2025-04-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT06333769

Locations: 🇨🇳
Jinjiang Municipal Hospital, Quanzhou, Fujian, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
The Second Hospital of Longyan, Longyan, Fujian, China

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Metastatic Nasopharyngeal Carcinoma
Intermittent Systematic Chemotherapy

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Paclitaxel protein-bound
Drug: Capecitabine
Drug: Tislelizumab

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 39

Registration Number: NCT06331845

Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury

Not Applicable

Recruiting

Conditions: Rectal Diseases
Radiation Injuries

Interventions: Drug: Triethanolamine cream

First Posted Date: 2024-03-22

Last Posted Date: 2024-06-05

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT06325982

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Phase 2

Conditions: EGFR/ ALK-negative Advanced NSCLC

Interventions: Drug: tislelizumab and metronomic oral vinorelbine

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT06260553

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy